BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals

Status: Active, not recruiting

Conditions: Primary Hyperoxaluria Type 1

Study type: Observational

Funder types: Industry

Identifiers

NCT04982393

EUPAS43242 (Registry Identifier)

ALN-GO1-007

Details and patient eligibility

About

The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.

Enrollment: 207 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of PH1, per physician's determination

Exclusion criteria

• Currently enrolled in a clinical trial for any investigational agent

Trial design

207 participants in 1 patient group

Patients with PH1

Description:

Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.